![](https://aiolux-shared.s3.us-east-2.amazonaws.com/aiolux-logo-mid.png)
Check out Investor Copilot custom GPT, which lets you enjoy ChatGPT functionality with recent financial information
Conversationally interact with ChatGPT to now analyze updated prices, technical indicators, financial statements, macro-economic/company news & more for Stocks, ETFs & Cryptos
Conversationally interact with ChatGPT to now analyze updated prices, technical indicators, financial statements, macro-economic/company news & more for Stocks, ETFs & Cryptos
[ADAP] Adaptimmune Therapeutics plc - Debt / Capital
Data updated 2024-Mar-23 (Saturday)Note: Detailed Statistics for Debt / Capital in Balance Sheet for Adaptimmune Therapeutics plc [NASDAQ:ADAP] with frequency distribution chart that analyze trends & history . Debt to Capital is a leverage ratio calculated as Total Liabilities / (Total Liabilities + Total Shareholder Equity). Debt to Equity Ratio measures financial risk considering proportion of debt that is being used to operate business. High Debt / Capital implies higher risk. View Balance Sheet for broader context
Share
Quarterly Debt / Capital values for Adaptimmune Therapeutics plc are rounded to enhance readability
2023-Dec | 2023-Sep | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sep | |
---|---|---|---|---|---|---|
Debt / Capital | 86.0% | 70.3% | 63.1% | 70.9% | 75.1% | 65.9% |
Sequential Quarter Growth | +22.4% | +11.4% | -11.0% | -5.6% | +14.0% | +3.8% |
Quarter-on Quarter Growth | +14.5% | +6.7% | -0.6% | +15.9% | +33.8% | +107.0% |
Annual Debt / Capital values for Adaptimmune Therapeutics plc are rounded to enhance readability
2023-Dec | 2022-Dec | 2021-Dec | 2020-Dec | 2019-Dec | 2018-Dec | |
---|---|---|---|---|---|---|
Debt / Capital | 86.0% | 75.1% | 56.1% | 24.4% | 31.9% | 10.8% |
Year-on-Year Growth | +14.5% | +33.8% | +130.5% | -23.6% | +195.6% | -61.2% |
2-yr CAGR | +23.8% | +75.6% | +32.7% | +50.3% | +7.1% | -39.2% |
3-yr CAGR | +52.3% | +33.0% | +73.3% | -4.3% | +3.0% | |
4-yr CAGR | +28.1% | +62.4% | +19.2% | -4.4% | ||
5-yr CAGR | +51.5% | +22.0% | +14.0% |
Frequency distribution of quarterly Debt / Capital values from 2015-Sep-30 grouped into buckets. Latest Debt / Capital value is 86 as of 2023-Dec-31
Subsequent stock performance post earnings date till next announcement for Adaptimmune Therapeutics plc mapped with quarterly Debt / Capital values reported at that time. Most recent value denoted with star
Select frequency and calculation type for Debt / Capital above for vertical axis in scatter chart. Additionally choose type of performance for horizontal axis
Bayesian (Conditional Probability) analysis for Adaptimmune Therapeutics plc with subsequent post-earnings performance given Debt / Capital values. Analysis uses quarterly data and subsequent relative performance benchmarked to S&P 500 index. Most recent quarter is denoted with a star and corresponding partial performance is excluded from calculations
Underperform (relative perf.) | Outperform (relative perf.) | |
---|---|---|
Debt / Capital - Low | 65% | 35% |
Debt / Capital - Medium | 56% | 44% |
Debt / Capital - High | 31% | 69% |
Debt / Capital (Sequential growth %) - Low | 74% | 26% |
Debt / Capital (Sequential growth %) - Medium | 31% | 69% |
Debt / Capital (Sequential growth %) - High | 41% | 59% |
Debt / Capital (QoQ growth %) - Low | 81% | 19% |
Debt / Capital (QoQ growth %) - Medium | 57% | 43% |
Debt / Capital (QoQ growth %) - High | 12% | 88% |
Related to Adaptimmune Therapeutics plc
Information for Adaptimmune Therapeutics plc
Current Detail : Recent daily/monthly performance & benchmark comparison
Historical Detail : Historical performance & related information using Time Machine
Financial Statements : Analyze Income Statement, Balance Sheet & Cashflow Statement and also compare with peers Currently Viewing
Bayesian Statement Classifier : Investigate historical financial statements to make probabalistic predictions using Artificial Intelligence
Anomaly Detection : Investigate unusual recent performance & technicals with historical context using AI
Historical Seasonality : Seasonal performance by calendar months
Technical History : Popular Technical indicator trends (RSI, MACD etc.)
Metric Deciles : Contextualizing recent performance & technical levels into historical decile buckets
Dollar Cost Averaging : Dollar Cost Average (DCA) over time in your portfolio
Moving Averages : Key Simple & Exponential Moving Averages
Historical Analogues : Insights from closest historical matches to recent performance using Artificial Intelligence
Chart Pattern Matching : Insights from similar historical charts to recent chart using Artificial Intelligence
News Stories : News stories on 2024-Jun-21 on Google
SEC Reports : Quarterly reports around 2024-Jun-21 on SEC Edgar
Compare Adaptimmune Therapeutics plc with other assets
Market Performance : Recent performance across covered assets
Historical Performance : Prior & Subsequent performance across assets on a historical date
Market Technicals : Technical indicator levels across covered assets
Market Seasonality : Seasonal performance by calendar months across covered assets
Pair Correlations : Performance Correlations with other assets
Beta : Volatility relative to the broad market
Performance Comparison : Visually compare/benchmark performance with other assets over time
Side-by-Side Comparison : Contrast with other assets over time in a side-by-side presentation
Sector : Health Care sector performance which includes Adaptimmune Therapeutics plc
Industry : Biotechnology industry performance which includes Adaptimmune Therapeutics plc